18 03, 2020

A CRISPR diagnostic for Covid-19 from @mammothbiosci

By | March 18th, 2020|Categories: Diagnostics Tech, Other stuff|0 Comments

Mammoth Biosciences, one of the two companies developing CRISPR as a diagnostic tool, submitted a medRxiv preprint showcasing their work on a Covid-19 assay. The SARS-CoV-2 DETECTR assay generate results in 30 minutes from from extracted patient sample RNA. The assay performs simultaneous reverse transcription […]

28 02, 2020

The biggest sequencer on the block – @MGI_BGI DNBSEQ Tx

By | February 28th, 2020|Categories: Next-generation sequencing|Tags: , |0 Comments

The announcement of the first $100 30x human genome (reagents only) from Rade Drmanac in the final slot at #AGBT20 means that@MGI_BGI’s DNBSeq Tx is going to be the biggest sequencer in the world. However. it remains to be seen if the $100 genome will be an […]

27 11, 2019

Evidence for the use of cfDNA Fragmentome for early detection and monitoring of cacner

By | November 27th, 2019|Categories: Diagnostics Tech, Methods and applications, Next-generation sequencing|0 Comments

In Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection researchers at the Institute of Human Genetics in Austria demonstrate the use of cfDNA for cancer detection and monitoring. The group performed deep ATAC-Seq and deep cfDNA nucleosome mapping to […]

20 11, 2019

@illumina response to CMA

By | November 20th, 2019|Categories: Uncategorized|6 Comments

Illumina’s response to the CMA’s recent findings that their acquisition of PacBio would be anti-competitive was published on the CMA website today. And both theirs, and PacBio’s stock are up (a little bit) as a result. Their suggested remedies include: To grant a perpetual, royalty-free, […]

31 10, 2019

CMA says no to @illumina @pacbio deal

By | October 31st, 2019|Categories: Next-generation sequencing|11 Comments

October 25th was my birthday so I’ve been on holiday and waited till I got back before writing this post. There’s been lots of other coverage e.g. GenomeWeb, Motley Fool. Keith at OmicsOmics included a bit more on the other NGS players and emerging technologies and is worth […]

8 10, 2019

@Illumina and @Qiagen’s IVD deal: what does it mean for NGS?

By | October 8th, 2019|Categories: Next-generation sequencing, Uncategorized|0 Comments

Yesterday Illumina and Qiagen announced a 15 year deal to partner on development of NGS in vitro diagnostic kits to run on Illumina sequencers. And Qiagen, more quietly, announced that development of the GeneReader platform will cease. The second piece of news is unsurprising; I’d written about Qiagens […]

30 07, 2019

£250M for early diagnosis research in UK

By | July 30th, 2019|Categories: Other stuff|0 Comments

The UK’s Industrial Strategy program just announced a £250 million program for early detection of disease. A public:private partnership with £79 million for the UK Govt plus £160 million from businesses and charities will be used to fund the Accelerating Detection of Disease programme. This […]

25 07, 2019

Will @Illumina succeed in buying @PacBio?

By | July 25th, 2019|Categories: Uncategorized|7 Comments

The current CMA report “Anticipated acquisition by Illumina, Inc. of Pacific Biosciences of California, Inc. Decision on relevant merger situation and substantial lessening of competition” makes for some interesting, if frustrating, reading. Interesting because of what the report says but frustrating because of the redaction […]

19 06, 2019

@Illumina moving into baseball?

By | June 19th, 2019|Categories: Uncategorized|1 Comment

OK so Illumina is not (to my knowledge) planing on sponsoring the San Diego Padres. The title of this post was inspired by a wonderful bit of mistaken transcription of the recent Goldman Sachs Healthcare conference presentation by Francis deSouza “sequencers today generate baseball”…I think […]

Load More Posts